{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-019326","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.829836+00:00","generated_at":"2026-05-21T04:35:49.441750+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rocket Pharma reports positive Phase 1 data for RP-A601 in PKP2-ACM","bullets":["RP-A601 well-tolerated; no dose-limiting toxicities in 3 patients with up to 12 months follow-up.","PKP2 protein expression increased ~110% and ~398% from baseline in 2 patients with low expression.","Improved RV function, KCCQ-12 scores (34-41 points), and NYHA class (II to I) in patients.","PVCs reduced 9-63%; NSVT episodes eliminated in one patient. No further dose escalation."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-019326","json":"https://secwatch.observer/filing/0001140361-25-019326.json","markdown":"https://secwatch.observer/filing/0001140361-25-019326.md","text":"https://secwatch.observer/filing/0001140361-25-019326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125019326/0001140361-25-019326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125019326/ef20049151_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:35:49.441750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}